JP2016510213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510213A5 JP2016510213A5 JP2015551852A JP2015551852A JP2016510213A5 JP 2016510213 A5 JP2016510213 A5 JP 2016510213A5 JP 2015551852 A JP2015551852 A JP 2015551852A JP 2015551852 A JP2015551852 A JP 2015551852A JP 2016510213 A5 JP2016510213 A5 JP 2016510213A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- iro compound
- composition according
- iro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750014P | 2013-01-08 | 2013-01-08 | |
| US61/750,014 | 2013-01-08 | ||
| PCT/US2014/010599 WO2014110081A1 (en) | 2013-01-08 | 2014-01-08 | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510213A JP2016510213A (ja) | 2016-04-07 |
| JP2016510213A5 true JP2016510213A5 (cg-RX-API-DMAC7.html) | 2016-12-28 |
| JP6385957B2 JP6385957B2 (ja) | 2018-09-05 |
Family
ID=51061112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551852A Expired - Fee Related JP6385957B2 (ja) | 2013-01-08 | 2014-01-08 | トール様受容体に基づく免疫応答を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9260719B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2943251B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6385957B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101898177B1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014205544B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015016420B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2896537C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1214191A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014110081A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2896537C (en) * | 2013-01-08 | 2021-10-12 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| US9688993B2 (en) | 2015-02-13 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Toll-like receptor 9 antagonist and methods of use thereof |
| US20190046638A1 (en) | 2016-04-01 | 2019-02-14 | Checkmate Pharmaceuticals, Inc. | Fc RECEPTOR-MEDIATED DRUG DELIVERY |
| JP7034951B2 (ja) | 2016-06-08 | 2022-03-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 操作されたウイルスベクターは炎症および免疫応答の誘導を低減する |
| CA3044484A1 (en) * | 2016-11-23 | 2018-05-31 | Berlin Cures GmbH | Aptamers for use in inhibition and/or suppression of tlr9 activation |
| WO2019094548A1 (en) | 2017-11-08 | 2019-05-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| WO2019160866A2 (en) | 2018-02-13 | 2019-08-22 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| AU2019251421B2 (en) | 2018-04-09 | 2025-05-01 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| DE60132471T2 (de) * | 2000-09-26 | 2009-01-15 | Idera Pharmaceuticals, Inc., Cambridge | Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen |
| US7176296B2 (en) * | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7105495B2 (en) * | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| WO2003035836A2 (en) * | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| WO2004064782A2 (en) * | 2003-01-16 | 2004-08-05 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| WO2005001055A2 (en) * | 2003-06-11 | 2005-01-06 | Hybridon, Inc. | Stabilized immunomodulatory oligonucleotides |
| CA2532926A1 (en) * | 2003-07-15 | 2005-02-03 | Hybridon, Inc. | Combined use of immunostimulatory oligonucleotides and cytokines or radiation |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| KR20070028537A (ko) * | 2004-06-15 | 2007-03-12 | 이데라 파마슈티칼즈, 인코포레이티드 | 면역자극 올리고누클레오티드 다량체 |
| US7498425B2 (en) * | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| US8383598B2 (en) | 2005-10-12 | 2013-02-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| CN104278037B (zh) * | 2005-10-12 | 2020-09-15 | 艾德拉药物股份有限公司 | 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物 |
| US8426375B2 (en) | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8399423B2 (en) | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US7776834B2 (en) * | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| US7709317B2 (en) * | 2005-11-14 | 2010-05-04 | International Business Machines Corporation | Method to increase strain enhancement with spacerless FET and dual liner process |
| CN101379195B (zh) * | 2005-12-20 | 2012-05-09 | 艾德拉药物股份有限公司 | 含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性 |
| KR101221589B1 (ko) * | 2006-04-07 | 2013-01-15 | 이데라 파마슈티칼즈, 인코포레이티드 | Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물 |
| US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| WO2008073959A2 (en) * | 2006-12-12 | 2008-06-19 | Idera Pharmaceuticals, Inc. | Synthetic agonists of tlr9 |
| US8713253B1 (en) * | 2007-06-18 | 2014-04-29 | Guidance-Tableau, Llc | Modular storage system |
| CA2692161C (en) * | 2007-07-09 | 2015-09-29 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory rna (simra) compounds |
| ES2539353T3 (es) * | 2007-08-01 | 2015-06-30 | Idera Pharmaceuticals, Inc. | Nuevos agonistas sintéticos de TLR9 |
| AU2008286735A1 (en) * | 2007-08-15 | 2009-02-19 | Idera Pharmaceuticals, Inc. | Toll like receptor modulators |
| WO2009154609A1 (en) * | 2008-06-17 | 2009-12-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| MX2011003625A (es) | 2008-10-06 | 2011-05-31 | Idera Pharmaceuticals Inc | Uso de inhibidores de receptores tipo toll en la prevencion y tratamiento de hipercolesterolemia e hiperlipidemia y enfermedades relacionadas con esto. |
| EP2437791B1 (en) * | 2009-06-01 | 2017-03-22 | Idera Pharmaceuticals, Inc. | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9 |
| WO2011041311A2 (en) | 2009-09-29 | 2011-04-07 | Yale University | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods |
| CN103153346A (zh) | 2010-06-16 | 2013-06-12 | 戴纳瓦克斯技术公司 | 使用tlr7和/或tlr9抑制剂的治疗方法 |
| EP2640420B1 (en) * | 2010-11-19 | 2018-08-15 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| JP6093759B2 (ja) * | 2011-06-01 | 2017-03-08 | ジャナス バイオセラピューティクス，インク． | 新規の免疫系調節剤 |
| US20140378537A1 (en) * | 2011-09-09 | 2014-12-25 | Genentech, Inc. | Treatment of th17 mediated inflammatory diseases |
| EP2836234B1 (en) * | 2012-04-12 | 2019-06-12 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
| CA2896537C (en) * | 2013-01-08 | 2021-10-12 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| CN105164970B (zh) * | 2013-05-30 | 2019-12-17 | 英特尔公司 | 自适应认证系统和方法 |
| US9688993B2 (en) * | 2015-02-13 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Toll-like receptor 9 antagonist and methods of use thereof |
-
2014
- 2014-01-08 CA CA2896537A patent/CA2896537C/en active Active
- 2014-01-08 EP EP14738139.6A patent/EP2943251B1/en not_active Not-in-force
- 2014-01-08 AU AU2014205544A patent/AU2014205544B2/en not_active Ceased
- 2014-01-08 KR KR1020157021207A patent/KR101898177B1/ko not_active Expired - Fee Related
- 2014-01-08 JP JP2015551852A patent/JP6385957B2/ja not_active Expired - Fee Related
- 2014-01-08 US US14/149,899 patent/US9260719B2/en not_active Expired - Fee Related
- 2014-01-08 HK HK16102283.4A patent/HK1214191A1/zh unknown
- 2014-01-08 BR BR112015016420-0A patent/BR112015016420B1/pt not_active IP Right Cessation
- 2014-01-08 WO PCT/US2014/010599 patent/WO2014110081A1/en not_active Ceased
-
2016
- 2016-01-08 US US14/990,929 patent/US10066230B2/en active Active
- 2016-07-13 US US15/209,333 patent/US10041076B2/en active Active
-
2018
- 2018-10-12 AU AU2018247308A patent/AU2018247308B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510213A5 (cg-RX-API-DMAC7.html) | ||
| JP2013544816A5 (cg-RX-API-DMAC7.html) | ||
| Velkov et al. | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead | |
| ES2967453T3 (es) | Compuestos de pirrolizina sustituidos y usos de los mismos | |
| JP2010536787A5 (cg-RX-API-DMAC7.html) | ||
| Gane | Future anti‐HBV strategies | |
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| JP2015513897A5 (cg-RX-API-DMAC7.html) | ||
| JP2015517489A5 (cg-RX-API-DMAC7.html) | ||
| JP2008056679A5 (cg-RX-API-DMAC7.html) | ||
| JP2006524669A5 (cg-RX-API-DMAC7.html) | ||
| JP2016538885A5 (cg-RX-API-DMAC7.html) | ||
| EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| PH12017500797A1 (en) | Substituted chromanes and methods of use | |
| JP2020508310A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501133A5 (cg-RX-API-DMAC7.html) | ||
| JP2017531002A5 (cg-RX-API-DMAC7.html) | ||
| JP2009533348A5 (cg-RX-API-DMAC7.html) | ||
| ES2897599T3 (es) | Mejora de la administración de genes a células asesinas naturales, células madre hematopoyéticas y macrófagos | |
| JP2017526728A5 (cg-RX-API-DMAC7.html) | ||
| PH12014500724A1 (en) | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | |
| JP2019506862A5 (cg-RX-API-DMAC7.html) | ||
| JP2016517446A5 (cg-RX-API-DMAC7.html) | ||
| EA202090465A1 (ru) | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний | |
| JP2018509380A5 (cg-RX-API-DMAC7.html) |